{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T21:45:38Z","timestamp":1787953538296,"version":"build-2784847793"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007705","name":"Astellas Pharma Global Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007705","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.urology.2020.09.040","type":"journal-article","created":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T04:52:57Z","timestamp":1602305577000},"page":"235-242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Mirabegron Vs Placebo Add-on Therapy in Men With Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Safety Analysis From the Randomized, Phase 4 PLUS Study"],"prefix":"10.1016","volume":"147","author":[{"given":"Sender","family":"Herschorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin T.","family":"McVary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Cambronero Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita M.","family":"Kristy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurul","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hairston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2020.09.040_bib0001","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.urology.2010.08.039","article-title":"National community prevalence of overactive bladder in the United States stratified by sex and age","volume":"77","author":"Coyne","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.urology.2020.09.040_bib0002","first-page":"71","article-title":"Review of the epidemiology of overactive bladder","volume":"8","author":"Eapen","year":"2016","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.urology.2020.09.040_bib0003","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1464-410X.2007.07198.x","article-title":"A population-based study of urinary symptoms and incontinence: the Canadian Urinary Bladder Survey","volume":"101","author":"Herschorn","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2020.09.040_bib0004","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1111\/j.1464-410X.2008.07601.x","article-title":"The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study","volume":"101","author":"Coyne","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2020.09.040_bib0005","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/nau.1001","article-title":"BPH with coexisting overactive bladder dysfunction\u2015an everyday urological dilemma","volume":"20","author":"Knutson","year":"2001","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2020.09.040_bib0006","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1464-410X.2004.05039.x","article-title":"Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder","volume":"94","author":"Lee","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2020.09.040_bib0007","unstructured":"Burkhard FC, Bosch JLHR, Cruz F, et al. EAU urinary incontinence guidelines 2018. Available at: https:\/\/uroweb.org\/guideline\/urinary-incontinence\/. Accessed September 29, 2020."},{"key":"10.1016\/j.urology.2020.09.040_bib0008","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/JU.0000000000000309","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment 2019","volume":"202","author":"Lightner","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.09.040_bib0009","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","article-title":"The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis","volume":"54","author":"Chapple","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.09.040_bib0010","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.eururo.2018.03.020","article-title":"Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis","volume":"74","author":"Kelleher","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.09.040_bib0011","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jamainternmed.2019.0677","article-title":"Anticholinergic drug exposure and the risk of dementia: a nested case-control study","volume":"179","author":"Coupland","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.urology.2020.09.040_bib0012","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jamainternmed.2014.7663","article-title":"Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study","volume":"175","author":"Gray","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.urology.2020.09.040_bib0013","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.juro.2011.01.074","article-title":"Update on AUA guideline on the management of benign prostatic hyperplasia","volume":"185","author":"McVary","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.09.040_bib0014","unstructured":"Flomaxtra XL, 400 micrograms, film-coated prolonged release tablet: summary of product characteristics (12 November 2019). Available at: https:\/\/www.medicines.org.uk\/emc\/product\/97\/smpc. Accessed September 29, 2020."},{"key":"10.1016\/j.urology.2020.09.040_bib0015","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/j.1464-410X.2008.07761.x","article-title":"Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score","volume":"102","author":"Kaplan","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2020.09.040_bib0016","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1757-5672.2010.00081.x","article-title":"Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics","volume":"3","author":"Nishizawa","year":"2011","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.urology.2020.09.040_bib0017","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.urology.2013.05.008","article-title":"Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite \u03b1-blocker treatment in patients with BPH: the ADDITION STUDY","volume":"82","author":"Takeda","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.urology.2020.09.040_bib0018","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/1756287217702797","article-title":"Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies","volume":"9","author":"Tubaro","year":"2017","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.urology.2020.09.040_bib0019","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.euf.2019.10.019","article-title":"Mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: a randomized, placebo-controlled study (MATCH)","volume":"6","author":"Kakizaki","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urology.2020.09.040_bib0020","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1097\/JU.0000000000000738","article-title":"Efficacy and safety of mirabegron versus placebo add-on therapy in men with overactive bladder symptoms receiving tamsulosin for underlying benign prostatic hyperplasia: a randomized, phase 4 study (PLUS)","volume":"203","author":"Kaplan","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.09.040_bib0021","unstructured":"MYRBETRIQ prescribing information. Revised April 2018. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/202611s011lbl.pdf. Accessed September 29, 2020."},{"key":"10.1016\/j.urology.2020.09.040_bib0022","unstructured":"MYRBETRIQ\u00ae product monograph. Revised: June 02, 2016. Available at: https:\/\/pdf.hres.ca\/dpd_pm\/00035298.PDF. Accessed September 29, 2020."},{"key":"10.1016\/j.urology.2020.09.040_bib0023","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.juro.2014.09.091","article-title":"A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction","volume":"193","author":"Ichihara","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.09.040_bib0024","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0149-2918(01)80022-9","article-title":"Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study","volume":"23","author":"Chrischilles","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.urology.2020.09.040_bib0025","first-page":"155","article-title":"Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group","volume":"29","author":"Chapple","year":"1996","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.09.040_bib0026","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/jcph.1107","article-title":"Cardiovascular safety of the \u03b23-adrenoceptor agonist mirabegron and the antimuscarinic agent solifenacin in the SYNERGY trial","volume":"58","author":"White","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.urology.2020.09.040_bib0027","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/j.1464-410X.2007.07162.x","article-title":"Tamsulosin Study Group. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome","volume":"100","author":"Robinson","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2020.09.040_bib0028","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1001\/jamainternmed.2019.2011","article-title":"Association of mirabegron with the risk of arrhythmia in adult patients 66 years or older\u2013a population-based cohort study","volume":"179","author":"Tadrous","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.urology.2020.09.040_bib0029","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.urology.2011.02.055","article-title":"Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms\u2015ASSIST, randomized controlled study","volume":"78","author":"Yamaguchi","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.urology.2020.09.040_bib0030","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.eururo.2012.10.048","article-title":"Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a \u03b23-adrenoceptor agonist, in overactive bladder","volume":"63","author":"Chapple","year":"2013","journal-title":"Eur Urol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429520312450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429520312450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T02:12:20Z","timestamp":1758766340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429520312450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":30,"alternative-id":["S0090429520312450"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2020.09.040","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mirabegron Vs Placebo Add-on Therapy in Men With Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Safety Analysis From the Randomized, Phase 4 PLUS Study","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2020.09.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}